QQQ   357.08 (+0.61%)
AAPL   172.57 (+0.10%)
MSFT   316.79 (+1.08%)
META   300.02 (-0.31%)
GOOGL   133.38 (+0.72%)
AMZN   126.78 (+1.65%)
TSLA   251.65 (+2.08%)
NVDA   438.43 (+0.75%)
NIO   8.63 (+0.23%)
BABA   84.13 (-0.48%)
AMD   101.04 (+0.96%)
T   14.57 (-1.42%)
F   12.02 (-0.41%)
MU   68.03 (+0.29%)
CGC   0.72 (+5.02%)
GE   108.11 (+0.32%)
DIS   79.41 (-0.16%)
AMC   7.95 (+1.27%)
PFE   33.79 (-0.32%)
PYPL   57.77 (+0.82%)
NFLX   377.00 (+0.07%)
QQQ   357.08 (+0.61%)
AAPL   172.57 (+0.10%)
MSFT   316.79 (+1.08%)
META   300.02 (-0.31%)
GOOGL   133.38 (+0.72%)
AMZN   126.78 (+1.65%)
TSLA   251.65 (+2.08%)
NVDA   438.43 (+0.75%)
NIO   8.63 (+0.23%)
BABA   84.13 (-0.48%)
AMD   101.04 (+0.96%)
T   14.57 (-1.42%)
F   12.02 (-0.41%)
MU   68.03 (+0.29%)
CGC   0.72 (+5.02%)
GE   108.11 (+0.32%)
DIS   79.41 (-0.16%)
AMC   7.95 (+1.27%)
PFE   33.79 (-0.32%)
PYPL   57.77 (+0.82%)
NFLX   377.00 (+0.07%)
QQQ   357.08 (+0.61%)
AAPL   172.57 (+0.10%)
MSFT   316.79 (+1.08%)
META   300.02 (-0.31%)
GOOGL   133.38 (+0.72%)
AMZN   126.78 (+1.65%)
TSLA   251.65 (+2.08%)
NVDA   438.43 (+0.75%)
NIO   8.63 (+0.23%)
BABA   84.13 (-0.48%)
AMD   101.04 (+0.96%)
T   14.57 (-1.42%)
F   12.02 (-0.41%)
MU   68.03 (+0.29%)
CGC   0.72 (+5.02%)
GE   108.11 (+0.32%)
DIS   79.41 (-0.16%)
AMC   7.95 (+1.27%)
PFE   33.79 (-0.32%)
PYPL   57.77 (+0.82%)
NFLX   377.00 (+0.07%)
QQQ   357.08 (+0.61%)
AAPL   172.57 (+0.10%)
MSFT   316.79 (+1.08%)
META   300.02 (-0.31%)
GOOGL   133.38 (+0.72%)
AMZN   126.78 (+1.65%)
TSLA   251.65 (+2.08%)
NVDA   438.43 (+0.75%)
NIO   8.63 (+0.23%)
BABA   84.13 (-0.48%)
AMD   101.04 (+0.96%)
T   14.57 (-1.42%)
F   12.02 (-0.41%)
MU   68.03 (+0.29%)
CGC   0.72 (+5.02%)
GE   108.11 (+0.32%)
DIS   79.41 (-0.16%)
AMC   7.95 (+1.27%)
PFE   33.79 (-0.32%)
PYPL   57.77 (+0.82%)
NFLX   377.00 (+0.07%)
NASDAQ:CHRS

Coherus BioSciences (CHRS) Stock Forecast, Price & News

$3.29
-0.06 (-1.79%)
(As of 09:57 AM ET)
Compare
Today's Range
$3.28
$3.41
50-Day Range
$3.35
$5.45
52-Week Range
$3.28
$10.99
Volume
149,090 shs
Average Volume
2.35 million shs
Market Capitalization
$310.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.63

Coherus BioSciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
336.6% Upside
$14.63 Price Target
Short Interest
Healthy
15.38% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.08
Upright™ Environmental Score
News Sentiment
0.31mentions of Coherus BioSciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.97) to $0.03 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

244th out of 965 stocks

Biological Products, Except Diagnostic Industry

35th out of 157 stocks


CHRS stock logo

About Coherus BioSciences (NASDAQ:CHRS) Stock

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

CHRS Price History

CHRS Stock News Headlines

Experts: "NVIDIA Bubble" Could Affect Entire Market
Several major analysts are warning that NVIDIA and other tech giants may have gotten “too big to succeed”.
Coherus BioSciences (NASDAQ:CHRS) Rating Reiterated by HC Wainwright
4 Analysts Have This to Say About Coherus BioSciences
Coherus (CHRS) Gets CRL for Udenyca Onbody, Shares Down
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
H.C. Wainwright Keeps Their Buy Rating on Coherus Biosciences (CHRS)
Analyst Ratings for Coherus BioSciences
See More Headlines
Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.

CHRS Company Calendar

Last Earnings
8/02/2023
Today
10/04/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CHRS
Fax
N/A
Employees
294
Year Founded
2010

Price Target and Rating

Average Stock Price Forecast
$14.63
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+336.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-291,750,000.00
Net Margins
-145.18%
Pretax Margin
-145.18%

Debt

Sales & Book Value

Annual Sales
$211.04 million
Book Value
($1.77) per share

Miscellaneous

Free Float
84,086,000
Market Cap
$316.47 million
Optionable
Optionable
Beta
0.95

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Dennis M. LanfearMr. Dennis M. Lanfear (Age 68)
    Chairman, Pres & CEO
    Comp: $1.79M
  • Mr. McDavid StilwellMr. McDavid Stilwell (Age 51)
    Chief Financial Officer
    Comp: $719.64k
  • Mr. Bryan J. Mcmichael (Age 45)
    Sr. VP of Accounting, Principal Accounting Officer & Corp. Controller
  • Mr. Richard L. Hameister
    Chief Technical Officer
  • Mr. Marek Ciszewski J.D.
    Sr. VP of Investor Relations
  • Mr. Christopher W. Slavinsky (Age 50)
    Chief Bus. & Legal Officer
  • Cheston Turbyfill
    VP of Communications
  • Ms. Rebecca Sunshine (Age 60)
    Chief HR Officer
  • Mr. Michael Chen
    Sr. VP of Commercial Analytics & Trade
  • Mr. Paul Reider (Age 54)
    Chief Commercial Officer













CHRS Stock - Frequently Asked Questions

Should I buy or sell Coherus BioSciences stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CHRS shares.
View CHRS analyst ratings
or view top-rated stocks.

What is Coherus BioSciences' stock price forecast for 2023?

7 brokerages have issued 1-year price targets for Coherus BioSciences' stock. Their CHRS share price forecasts range from $8.00 to $23.00. On average, they expect the company's share price to reach $14.63 in the next year. This suggests a possible upside of 336.6% from the stock's current price.
View analysts price targets for CHRS
or view top-rated stocks among Wall Street analysts.

How have CHRS shares performed in 2023?

Coherus BioSciences' stock was trading at $7.92 on January 1st, 2023. Since then, CHRS shares have decreased by 57.7% and is now trading at $3.35.
View the best growth stocks for 2023 here
.

Are investors shorting Coherus BioSciences?

Coherus BioSciences saw a decrease in short interest in September. As of September 15th, there was short interest totaling 14,530,000 shares, a decrease of 7.2% from the August 31st total of 15,650,000 shares. Based on an average daily trading volume, of 2,990,000 shares, the short-interest ratio is currently 4.9 days.
View Coherus BioSciences' Short Interest
.

When is Coherus BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our CHRS earnings forecast
.

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences, Inc. (NASDAQ:CHRS) announced its quarterly earnings data on Wednesday, August, 2nd. The biotechnology company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.66) by $0.17. The biotechnology company earned $58.72 million during the quarter, compared to analyst estimates of $50.83 million.

What ETFs hold Coherus BioSciences' stock?

ETFs with the largest weight of Coherus BioSciences (NASDAQ:CHRS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA).First Trust Innovation Leaders ETF (ILDR).

What guidance has Coherus BioSciences issued on next quarter's earnings?

Coherus BioSciences updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $275.00M-, compared to the consensus revenue estimate of $266.16 million.

What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?

21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Coherus BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

What is Coherus BioSciences' stock symbol?

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

How do I buy shares of Coherus BioSciences?

Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Coherus BioSciences' stock price today?

One share of CHRS stock can currently be purchased for approximately $3.35.

How much money does Coherus BioSciences make?

Coherus BioSciences (NASDAQ:CHRS) has a market capitalization of $316.47 million and generates $211.04 million in revenue each year. The biotechnology company earns $-291,750,000.00 in net income (profit) each year or ($3.32) on an earnings per share basis.

How many employees does Coherus BioSciences have?

The company employs 294 workers across the globe.

Does Coherus BioSciences have any subsidiaries?
The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..
Read More
How can I contact Coherus BioSciences?

Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The official website for the company is www.coherus.com. The biotechnology company can be reached via phone at (650) 649-3530 or via email at darrington@coherus.com.

This page (NASDAQ:CHRS) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -